Patents Assigned to Novartis AG
  • Patent number: 11510912
    Abstract: The present invention provides compounds of formula I: or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds, and methods of using such compounds for treatment of joint damage or joint injury in a mammal, and for inducing differentiation of mesenchymal stem cells into chondrocytes.
    Type: Grant
    Filed: April 14, 2020
    Date of Patent: November 29, 2022
    Assignee: Novartis AG
    Inventors: Ha-Soon Choi, James Paul Lajiness, Srinivasa Reddy Natala, Bao Nguyen, Hank Michael James Petrassi, Zhicheng Wang
  • Patent number: 11512335
    Abstract: The present application pertains inter alia to an isolated vertebrate cell suitable for recombinant expression of a polypeptide of interest, wherein the vertebrate cell is altered to impair the function of the endogenous protease matriptase and wherein the cell comprises at least one heterologous polynucleotide encoding a polypeptide of interest and wherein the polypeptide of interest is secreted by the cell. It was found that using respective vertebrate cells for producing a recombinant polypeptide of interest significantly reduces clipping of the polypeptide of interest that is secreted into the cell culture medium. Also provided are improved production and screening methods.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: November 29, 2022
    Assignee: Novartis AG
    Inventors: Holger Laux, Sandrine Romand, Ursula Bodendorf
  • Patent number: 11505541
    Abstract: PKC inhibitors are disclosed. The PKC inhibitors are useful for treating PKC associated diseases, including certain cancers. The PKC inhibitors have improved efficacy at lower dosage amounts to achieve tumor regression, improved potency, PK profile, absorption, gastrointestinal tolerance and kinase selectivity.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: November 22, 2022
    Assignee: Novartis AG
    Inventors: Michael Joseph Luzzio, Julien Papillon, Michael Scott Visser
  • Patent number: 11504333
    Abstract: The invention pertains to dispersible tablets comprising as active ingredient N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, methanesulfonate salt, processes for preparing the same, and processes for using the same.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: November 22, 2022
    Assignee: Novartis AG
    Inventors: Nikos Karanikolopoulos, Paul Anthony Goulding
  • Publication number: 20220363735
    Abstract: The present invention relates to anti-VP 1 antibodies, antibody fragments, and their uses for the prevention and treatment of polyoma virus infection and associated diseases.
    Type: Application
    Filed: October 15, 2021
    Publication date: November 17, 2022
    Applicant: Novartis AG
    Inventors: Johanna ABEND, Zorica DRAGIC, Adam Lloyd FEIRE, Mark KNAPP, Steven KOVACS, Elisabetta TRAGGIAI, Lichun WANG, Yongqiang WANG, Danqing WU, Qilong WU, Fangmin Xu
  • Patent number: 11492409
    Abstract: The present disclosure provides BCMA binding molecules that specifically bind to human BCMA, conjugates comprising the BCMA binding molecules, and pharmaceutical compositions comprising the BCMA binding molecules and the conjugates. The disclosure further provides methods of using the BCMA binding molecules to treat cancers that express cell surface BCMA. The disclosure yet further provides recombinant host cells engineered to express the BCMA binding molecules and methods of producing the BCMA binding molecules by culturing the host cells under conditions in which the BCMA binding molecules are expressed.
    Type: Grant
    Filed: May 30, 2019
    Date of Patent: November 8, 2022
    Assignee: Novartis AG
    Inventors: Aida Abujoub, John Blankenship, Tony Fleming, Brian Holmberg, Connie Hong, Lu Huang, Haihui Lu
  • Patent number: 11492402
    Abstract: The present invention provides antibodies that bind to and stabilize human Triggering Receptor Expressed on Myeloid cells 2 (TREM2) protein and methods of using these antibodies.
    Type: Grant
    Filed: October 14, 2019
    Date of Patent: November 8, 2022
    Assignee: NOVARTIS AG
    Inventors: Verena Brand, Dominik Feuerbach, Fabrizio Gasparini, Nathalie George, Eveline Schaadt, Derya Shimshek, Honnappa Srinivas, Markus Waldhuber, Rainer Wilcken
  • Patent number: 11485742
    Abstract: Provided herein are compounds according to Formula (I) or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, and R7 are defined herein. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) as well as the use of such compounds as M4 receptor agonists.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: November 1, 2022
    Assignee: NOVARTIS AG
    Inventors: Amy Calhoun, Xin Chen, Kevin Matthew Gardinier, Edward Charles Hall, Keith Jendza, Nancy Labbe-Giguere, James Neef, Daniel Steven Palacios, Ming Qian, Michael David Shultz, Christopher G. Thomson, Kate Yaping Wang, Fan Yang
  • Publication number: 20220340591
    Abstract: In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein.
    Type: Application
    Filed: October 12, 2018
    Publication date: October 27, 2022
    Applicant: Novartis AG
    Inventors: Shankar VENKATRAMAN, Shomir GHOSH, William R. ROUSH, Dong-Ming SHEN, Jason KATZ, Hans Martin SEIDEL
  • Patent number: 11478480
    Abstract: The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.
    Type: Grant
    Filed: February 13, 2020
    Date of Patent: October 25, 2022
    Assignee: Novartis AG
    Inventors: Joseph Paul Bullock, Chinmay Maheshwari, Quintus Medley, Muneto Mogi, Michela Montecchi-Palmer, Kalliopi Stasi
  • Patent number: 11480570
    Abstract: The invention relates, in part, to methods of deriving a value for % biomarker positivity (PBP) for all cells or optionally, one or more subsets thereof, present in a field of view of a tissue sample from a cancer patient. The values for PBP can be indicative of a patient's response to immunotherapy.
    Type: Grant
    Filed: October 21, 2016
    Date of Patent: October 25, 2022
    Assignee: NOVARTIS AG
    Inventors: Naveen Dakappagari, Jennifer Bordeaux, Thai Tran, Ju Young Kim
  • Patent number: 11473083
    Abstract: Provided herein are compositions and methods for decreasing tau mRNA and protein expression. These compositions and methods are useful in treating tau-related diseases and disorders.
    Type: Grant
    Filed: December 19, 2016
    Date of Patent: October 18, 2022
    Assignee: NOVARTIS AG
    Inventors: Manuela Polydoro Ofengeim, Jan Weiler
  • Patent number: 11466023
    Abstract: A combination comprising a Mcl-1 inhibitor and a second anticancer agent, wherein the second anticancer agent is selected from anthracyclines, cytarabine and hypomethylating agents, and compositions and uses thereof.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: October 11, 2022
    Assignees: LES LABORATOIRES SERVIER, NOVARTIS AG
    Inventors: Andrew Wei, Donia Moujalled, Giovanna Pomilio, Olivier Geneste, Ana Leticia Maragno
  • Patent number: 11466271
    Abstract: The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.
    Type: Grant
    Filed: February 5, 2018
    Date of Patent: October 11, 2022
    Assignees: Novartis AG
    Inventors: Craig Stephen Mickanin, Christian Schmedt, Jennifer Snead, Susan Stevenson, Yi Yang
  • Patent number: 11464871
    Abstract: Processes for precipitating polymers from a polymer-containing solution are disclosed.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: October 11, 2022
    Assignee: Novartis AG
    Inventor: J. Michael Ramstack
  • Patent number: 11466048
    Abstract: The disclosure relates to nucleic acids that contain modifications at the 5?-end, 3?-end or 5?-end and 3?-ends, and compounds that can be used to make the modified nucleic acids are disclosed. The modified nucleic acids have improved expression, lower immunogenicity and improved stability compared to unmodified nucleic acids.
    Type: Grant
    Filed: February 26, 2020
    Date of Patent: October 11, 2022
    Assignee: NOVARTIS AG
    Inventors: David Barnes-Seeman, Scott Louis Cohen, John Louis Diener, Christian Gampe, James Roache, Amy White, Sarah Louise Williams, Jun Yuan, Frederic Zecri
  • Patent number: 11458138
    Abstract: The present invention is related to 6-6 Fused Bicyclic Heteroaryl Compounds of the Formula A2 or A1 and their Use as LATS Inhibitors, or a salt, stereoisomer or pharmaceutical composition thereof; wherein the variables are as defined herein. The present invention further relates to a method of LATS inhibition in a cell population using a compound of Formula A1, or a salt, stereoisomer or pharmaceutical composition thereof. The present invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, their use in the treatment and management of diseases or disorders.
    Type: Grant
    Filed: April 26, 2018
    Date of Patent: October 4, 2022
    Assignee: Novartis AG
    Inventors: Dirk Behnke, Frada Berenshteyn, Xueshi Hao, Timothy Hoffman, Qihui Jin, Arnaud Lacoste, Cameron Lee, Jun Liu, Yahu Liu, Juergen Klaus Maibaum, Tingting Mo, Jianfeng Pan, Xin Qu, Jan Tchorz, Yun Feng Xie, Shanshan Yan, Yefen Zou
  • Patent number: 11459390
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of a tumor antigen as described herein. The invention also relates to nucleic acids comprising a truncated PGK promoter operably linked to a chimeric antigen receptor (CAR) specific to a tumor antigen as described herein, vectors encoding the same, and recombinant T cells comprising the CARs of the present invention. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an antigen binding domain that binds to a tumor antigen as described herein.
    Type: Grant
    Filed: January 15, 2016
    Date of Patent: October 4, 2022
    Assignees: Novartis AG, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Jennifer Brogdon, Hilmar Erhard Ebersbach, David Glass, Thomas Huber, Julia Jascur, Carl H. June, Jihyun Lee, Joan Mannick, Michael C. Milone, Leon Murphy, Avery D. Posey, Huijuan Song, Yongqiang Wang, Lai Wei, Qilong Wu, Qiumei Yang, Jiquan Zhang
  • Patent number: 11453651
    Abstract: The present invention describes novel heteroaryl butanoic acid derivatives that are good drug candidates especially with regard to leukotriene A4 hydrolase (LTA4H). The present invention also relates to pharmaceutical compositions comprising said novel heteroaryl butanoic acid derivatives, methods of using said compounds in the treatment of various diseases and disorders, and processes for preparing the said novel compounds.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: September 27, 2022
    Assignee: Novartis AG
    Inventors: Birgit Bollbuck, Christian Markert, Wolfgang Miltz, Till Roehn
  • Patent number: 11453677
    Abstract: The present invention provides a compound of Formula (I) including pharmaceutically acceptable salts thereof: (I) and therapeutic uses of these compounds. The invention further provides pharmaceutical compositions comprising these compounds, compositions comprising these compounds with a therapeutic co-agent, and methods of using the compounds and compositions to treat viral infections.
    Type: Grant
    Filed: July 20, 2020
    Date of Patent: September 27, 2022
    Assignee: Novartis AG
    Inventors: Rama Jain, Dennis Christofer Koester, James R. Manning, James Clifford Sutton, Benjamin Robert Taft, Lifeng Wan, Qian Zhao